Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

PF-05314882 selectively activates androgen receptors without much effect on prostate and may help in prostate cancer treatment and hair loss prevention.

Therapies targeting the androgen receptor are being developed to treat prostate cancer and improve bone and muscle health.

Activating androgen receptors in muscle can increase muscle mass and reduce fat.

Exemestane may protect bones by stimulating osteoblast growth through androgen-related pathways.

SARMs work differently in tissues due to unique interactions and structures.

Anabolic steroids boost muscle growth, SARMs increase muscle mass and bone density without side effects, and myostatin inhibitors block a protein that stops muscle growth, but each has potential risks.

Some synthesized compounds were more effective than Finasteride in reducing prostate cancer cell growth and androgen levels.

SARMs may be an effective treatment for a certain type of breast cancer by blocking cancer growth and spread.

Modified steroidal inhibitors showed promise in treating hormone-dependent cancers.

Vepdegestrant may become the first FDA-approved PROTAC degrader, marking a new era in drug development.

Improved CRBN ligands make protein degraders more effective and drug-like.

Promising cancer treatments were found, but the manufacturer closed.

New compounds were made and tested, with compound 6 showing potential for treating prostate-related diseases.

We need better ways to test and understand SARMs to make safer and more effective treatments.

The combination treatment showed a higher response rate but no significant survival benefits.

Aromatase inhibitors can cause various adverse reactions, so monitoring is crucial.

Strontium ranelate is no longer available for treatment.

Breast cancer treatments work better with AR activation, improving results and reducing side effects.

Loop diuretics may double bone loss in elderly men, finasteride lowers prostate cancer risk but may increase high-grade tumors, abarelix reduces testosterone quickly, and transdermal testosterone offers minimal sexual benefit for women.

SARM-induced changes in the androgen receptor are specific to each ligand and affect stability and protein interactions.

Certain ESR1 gene variations may affect hormone levels and fat distribution in women with high male hormone levels.

Ezetimibe effectively reduces prostate size in cases of benign prostatic hyperplasia.

Scientists have developed a new method to detect steroid abuse in athletes using cell-based tests, which could be the future of anti-doping methods.

Including androgens in hormone therapy may lower breast cancer risk.

The inhibitor affects androgen metabolism but not ovarian function.

A brominated phenoxy compound effectively inhibits a human enzyme and shows potential for clinical use.